GoAI
Get started
WuXi XDC Cayman Inc logo

WuXi XDC Cayman Inc

2268.HK

HKSEHealthcareMedical - Diagnostics & Research

Open in GoAI

Latest quote

HK$69.80

−HK$1.85 · -2.58%

Aug 24, 4:08 PM HKT

2268.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

WuXi XDC Cayman Inc. operates as an investment holding company and a global contract research, development, and manufacturing organization (CRDMO), with operations spanning China, North America, Europe, and other international regions. The company's expertise covers the entire lifecycle, from discovery and research to development and manufacturing, of biopharmaceutical products. Specifically, it focuses on antibody-drug conjugates (ADCs), various bioconjugates, monoclonal antibody intermediates, and the crucial payload-linkers integral to bioconjugate synthesis. Founded in 2013 and headquartered in Wuxi, China, WuXi XDC Cayman Inc. is a subsidiary of WuXi Biologics (Cayman) Inc.

Industry
Medical - Diagnostics & Research
Sector
Healthcare
Headquarters
CN
CEO
Jincai Li
Listed since
Nov 17, 2023
Employees
2,662

Market position

Day range

Current HK$69.80

52-week range

Current HK$69.80

Open
HK$71.30
Previous close
HK$71.65
Volume
9.48M
1.64× average
Average volume
5.78M
Average daily volume
Market cap
88.39B HKD
Beta
-0.78
Market reference 1
50-day average
HK$57.0866
+22.27% above average
200-day average
HK$60.7346
+14.93% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
71.5B CNY
P/E (TTM)
49.88×
P/B (TTM)
7.45×
P/S (TTM)
12.75×
EV / EBITDA
40.48×
Earnings yield
2.05%
Free cash flow yield
0.88%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
35.99%
Operating margin
27.26%
Net margin
24.91%
Return on equity
13.80%
Return on assets
10.25%
Return on invested capital
11.89%

Financial health

Debt / equity
0.08×
Current ratio
2.68×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends39%29%20%10%Gross margin, FY2021: 36.48%Gross margin, FY2022: 26.36%Gross margin, FY2023: 26.35%Gross margin, FY2024: 30.60%Gross margin, FY2025: 35.99%Operating margin, FY2021: 19.33%Operating margin, FY2022: 12.71%Operating margin, FY2023: 17.21%Operating margin, FY2024: 23.41%Operating margin, FY2025: 27.26%Net margin, FY2021: 17.65%Net margin, FY2022: 15.72%Net margin, FY2023: 13.35%Net margin, FY2024: 26.40%Net margin, FY2025: 24.91%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 36.48%. Gross margin FY2022 26.36%. Gross margin FY2023 26.35%. Gross margin FY2024 30.60%. Gross margin FY2025 35.99%. Operating margin FY2021 19.33%. Operating margin FY2022 12.71%. Operating margin FY2023 17.21%. Operating margin FY2024 23.41%. Operating margin FY2025 27.26%. Net margin FY2021 17.65%. Net margin FY2022 15.72%. Net margin FY2023 13.35%. Net margin FY2024 26.40%. Net margin FY2025 24.91%.

Income trends

Revenue

5.94B CNY+46.69%

Operating income

1.62B CNY+70.86%

Net income

1.48B CNY+38.41%
Income trends across reported periods6.53B CNY4.18B CNY1.82B CNY−534M CNYRevenue, FY2021: 311.13M CNYRevenue, FY2022: 990.42M CNYRevenue, FY2023: 2.12B CNYRevenue, FY2024: 4.05B CNYRevenue, FY2025: 5.94B CNYOperating income, FY2021: 60.13M CNYOperating income, FY2022: 125.89M CNYOperating income, FY2023: 365.5M CNYOperating income, FY2024: 948.54M CNYOperating income, FY2025: 1.62B CNYNet income, FY2021: 54.93M CNYNet income, FY2022: 155.73M CNYNet income, FY2023: 283.54M CNYNet income, FY2024: 1.07B CNYNet income, FY2025: 1.48B CNYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 311.13M CNY. Revenue FY2022 990.42M CNY. Revenue FY2023 2.12B CNY. Revenue FY2024 4.05B CNY. Revenue FY2025 5.94B CNY. Operating income FY2021 60.13M CNY. Operating income FY2022 125.89M CNY. Operating income FY2023 365.5M CNY. Operating income FY2024 948.54M CNY. Operating income FY2025 1.62B CNY. Net income FY2021 54.93M CNY. Net income FY2022 155.73M CNY. Net income FY2023 283.54M CNY. Net income FY2024 1.07B CNY. Net income FY2025 1.48B CNY.
Metric (CNY)FY2025FY2024FY2023FY2022FY2021
Revenue5.94B CNY4.05B CNY2.12B CNY990.42M CNY311.13M CNY
Cost of goods sold3.8B CNY2.81B CNY1.56B CNY729.34M CNY197.64M CNY
Gross profit2.14B CNY1.24B CNY559.56M CNY261.08M CNY113.49M CNY
Research and development147.21M CNY99.96M CNY76.87M CNY33.84M CNY13.82M CNY
Selling, general, and administrative334.57M CNY220.32M CNY139.19M CNY57.98M CNY29.89M CNY
Operating expenses518.63M CNY291.31M CNY194.06M CNY135.19M CNY42.8M CNY
Interest income183.82M CNY185.19M CNY47.36M CNY4.61M CNY28K CNY
Interest expense16.97M CNY3.21M CNY742K CNY2.92M CNY493K CNY
Depreciation and amortization145.42M CNY110.39M CNY54.78M CNY25.85M CNY18.14M CNY
Operating income1.62B CNY948.54M CNY365.5M CNY125.89M CNY60.13M CNY
Net income1.48B CNY1.07B CNY283.54M CNY155.73M CNY54.93M CNY

Company facts updated Aug 24, 2026.

Earnings

Latest fiscal-year EPS
1.12
FY2025 · +34.94% year over year
Latest fiscal-year revenue
5.94B CNY
FY2025 · +46.69% year over year

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual EPS trend1.230.80.37-0.06FY21FY22FY23FY24FY25

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual revenue trend6.51B4.25B2B-252.18MFY21FY22FY23FY24FY25

2268.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$197.4

-4.08%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.66

-3.20%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$221.4

-2.89%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$48.42

-5.06%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.10

-5.99%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$99.45

-2.88%

ETFs holding 2268.HK

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Total International Stock ETF logoVanguard Total International Stock ETFVXUS
Market value
37.52M
Weight
0.01%
AUM
646.2B USD
Expense ratio
0.05%
Price / 1D
$87.71+0.78%
Vanguard FTSE Emerging Markets ETF logoVanguard FTSE Emerging Markets ETFVWO
Market value
36.19M
Weight
0.02%
AUM
162.3B USD
Expense ratio
0.06%
Price / 1D
$60.45+0.72%
iShares MSCI Emerging Markets ETF logoiShares MSCI Emerging Markets ETFEEM
Market value
8.49M
Weight
0.03%
AUM
31.22B USD
Expense ratio
0.72%
Price / 1D
$67.12+0.75%
iShares MSCI China ETF logoiShares MSCI China ETFMCHI
Market value
8.08M
Weight
0.13%
AUM
6.29B USD
Expense ratio
0.59%
Price / 1D
$55.66+0.27%
Vanguard FTSE All-World ex-US ETF logoVanguard FTSE All-World ex-US ETFVEU
Market value
6M
Weight
0.01%
AUM
95.9B USD
Expense ratio
0.04%
Price / 1D
$85.69+0.82%
iShares Core MSCI Total International Stock ETF logoiShares Core MSCI Total International Stock ETFIXUS
Market value
5.31M
Weight
0.01%
AUM
60.91B USD
Expense ratio
0.07%
Price / 1D
$97.945+0.76%
Schwab Emerging Markets Equity ETF logoSchwab Emerging Markets Equity ETFSCHE
Market value
4.23M
Weight
0.03%
AUM
12.89B USD
Expense ratio
0.06%
Price / 1D
$36.97+0.71%
Dimensional - Emerging Core Equity Market ETF logoDimensional - Emerging Core Equity Market ETFDFAE
Market value
2.7M
Weight
0.03%
AUM
10B USD
Expense ratio
0.29%
Price / 1D
$39.49+0.51%

Continue in GoAI

Research 2268.HK

research.disclaimer